248 related articles for article (PubMed ID: 25209187)
21. [Progress of chemotherapy in colorectal cancer].
Komatsu Y
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1771-6. PubMed ID: 18064761
[No Abstract] [Full Text] [Related]
22. Identification of the biomarkers for the prediction of efficacy in first-line chemotherapy of metastatic colorectal cancer patients using SELDI-TOF-MS and artificial neural networks.
Yuan Y; Tan CW; Shen H; Yu JK; Fang XF; Jiang WZ; Zheng S
Hepatogastroenterology; 2012; 59(120):2461-5. PubMed ID: 22497949
[TBL] [Abstract][Full Text] [Related]
23. [The future of chemotherapy at home--from outpatient chemotherapy to chemotherapy at home].
Takahashi K
Gan To Kagaku Ryoho; 2006 Dec; 33 Suppl 2():279-81. PubMed ID: 17469360
[TBL] [Abstract][Full Text] [Related]
24. Patterns of treatment with chemotherapy and monoclonal antibodies for metastatic colorectal cancer in Western Europe.
Zhao Z; Pelletier E; Barber B; Bhosle M; Wang S; Gao S; Klingman D
Curr Med Res Opin; 2012 Feb; 28(2):221-9. PubMed ID: 22171947
[TBL] [Abstract][Full Text] [Related]
25. Central venous access port-related complications in outpatient chemotherapy for colorectal cancer.
Inaba Y; Yamaura H; Sato Y; Najima M; Shimamoto H; Nishiofuku H; Ura T; Muro K
Jpn J Clin Oncol; 2007 Dec; 37(12):951-4. PubMed ID: 18057011
[TBL] [Abstract][Full Text] [Related]
26. [IFL].
Yamazaki K; Yoshino T; Boku N
Gan To Kagaku Ryoho; 2006 Jul; 33(7):907-10. PubMed ID: 16835478
[TBL] [Abstract][Full Text] [Related]
27. Carboxylesterase isoform 2 mRNA expression in peripheral blood mononuclear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients.
Cecchin E; Corona G; Masier S; Biason P; Cattarossi G; Frustaci S; Buonadonna A; Colussi A; Toffoli G
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6901-7. PubMed ID: 16203781
[TBL] [Abstract][Full Text] [Related]
28. Stable disease in advanced colorectal cancer: therapeutic implications.
Pasetto LM; D'Andrea MR; Jirillo A; Rossi E; Monfardini S
Anticancer Res; 2006; 26(1B):511-22. PubMed ID: 16739312
[TBL] [Abstract][Full Text] [Related]
29. [The optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients].
Kawabata Y; Nakagawa A; Uchikoshi H; Tamiya Y
Yakugaku Zasshi; 2009 Mar; 129(3):359-64. PubMed ID: 19252394
[TBL] [Abstract][Full Text] [Related]
30. [Optimal volume of medicinal solution in the portable disposable infusion pump (SUREFUSER A) for FOLFOX6, FOLFIRI therapy of colorectal cancer patients (2nd report)-influence of temperature on outflow speed of the medicinal solution].
Kawabata Y; Nakagawa A
Yakugaku Zasshi; 2010 Apr; 130(4):621-7. PubMed ID: 20372010
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer Therapies.
Hossain F; Al-Khami AA; Wyczechowska D; Hernandez C; Zheng L; Reiss K; Valle LD; Trillo-Tinoco J; Maj T; Zou W; Rodriguez PC; Ochoa AC
Cancer Immunol Res; 2015 Nov; 3(11):1236-47. PubMed ID: 26025381
[TBL] [Abstract][Full Text] [Related]
32. TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages.
Liu Z; Xie Y; Xiong Y; Liu S; Qiu C; Zhu Z; Mao H; Yu M; Wang X
Cancer Lett; 2020 Jan; 469():173-185. PubMed ID: 31629935
[TBL] [Abstract][Full Text] [Related]
33. Albumin-stabilized layered double hydroxide nanoparticles synergized combination chemotherapy for colorectal cancer treatment.
Li L; Qian Y; Sun L; Han FY; Zhang R; Wang PY; Xu ZP
Nanomedicine; 2021 Jun; 34():102369. PubMed ID: 33636347
[TBL] [Abstract][Full Text] [Related]
34. Paclitaxel promotes differentiation of myeloid-derived suppressor cells into dendritic cells in vitro in a TLR4-independent manner.
Michels T; Shurin GV; Naiditch H; Sevko A; Umansky V; Shurin MR
J Immunotoxicol; 2012; 9(3):292-300. PubMed ID: 22283566
[TBL] [Abstract][Full Text] [Related]
35. Restoration of antitumor immunity through selective inhibition of myeloid derived suppressor cells by anticancer therapies.
Apetoh L; Végran F; Ladoire S; Ghiringhelli F
Curr Mol Med; 2011 Jul; 11(5):365-72. PubMed ID: 21568934
[TBL] [Abstract][Full Text] [Related]
36. Impaired SNX9 Expression in Immune Cells during Chronic Inflammation: Prognostic and Diagnostic Implications.
Ish-Shalom E; Meirow Y; Sade-Feldman M; Kanterman J; Wang L; Mizrahi O; Klieger Y; Baniyash M
J Immunol; 2016 Jan; 196(1):156-67. PubMed ID: 26608909
[TBL] [Abstract][Full Text] [Related]
37. Combination of irinotecan (CPT11) and 5-fluorouracil with an analysis of cellular determinants of drug activity.
Pavillard V; Formento P; Rostagno P; Formento JL; Fischel JL; Francoual M; Etienne MC; Milano G
Biochem Pharmacol; 1998 Nov; 56(10):1315-22. PubMed ID: 9825730
[TBL] [Abstract][Full Text] [Related]
38. Myeloid-derived suppressor cells in malignant melanoma.
Umansky V; Sevko A; Gebhardt C; Utikal J
J Dtsch Dermatol Ges; 2014 Nov; 12(11):1021-7. PubMed ID: 25263083
[TBL] [Abstract][Full Text] [Related]
39. Pi (Spleen)-deficiency syndrome in tumor microenvironment is the pivotal pathogenesis of colorectal cancer immune escape.
Sun XG; Lin XC; Diao JX; Yu ZL; Li K
Chin J Integr Med; 2016 Oct; 22(10):789-94. PubMed ID: 26556710
[TBL] [Abstract][Full Text] [Related]
40. Low cytosine triphosphate synthase 2 expression renders resistance to 5-fluorouracil in colorectal cancer.
Tan WL; Bhattacharya B; Loh M; Balasubramanian I; Akram M; Dong D; Wong L; Thakkar B; Salto-Tellez M; Soo RA; Fichtner I; Iacopetta B; Soong R
Cancer Biol Ther; 2011 Mar; 11(6):599-608. PubMed ID: 21378502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
